Learn About Homozygous Familial Hypercholesterolemia (HoFH)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Homozygous Familial Hypercholesterolemia (HoFH) Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the Latest Advances for Homozygous Familial Hypercholesterolemia (HoFH)?
Lipoprotein apheresis in patients with familial hypercholesterolemia: a single center research.
Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases.
Tired of the same old research?
Check Latest Advances
Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
What are the latest Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials?
HoFH, the International Clinical Collaborators - A Global HoFH Data-sharing Platform

Summary: Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)

Summary: This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).